Payment overview · 2025
General Payments
$1,048.55
44 reported records · 15 companies
Healthcare provider profile · identity verified
Saeed Kahkeshani, MD
Allopathic & Osteopathic Physicians|Pediatrics|Neurodevelopmental Disabilities · BAYTOWN, TX · NPI 1417006313
Verified facts
What the public records show
CMS Open Payments records show Saeed Kahkeshani, MD received $1,048.55 in general payments during 2025 across 44 reported records.
SK Life Science, Inc. accounted for 22.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
SK Life Science, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XCOPRI as an associated drug or biological on 1992 records involving 782 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Xcopri by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$232.12 | 22.1% | 9 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $170.45 | 16.3% | 9 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $142.41 | 13.6% | 7 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $93.93 | 9.0% | 3 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $61.21 | 5.8% | 2 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $57.69 | 5.5% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $55.75 | 5.3% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $43.64 | 4.2% | 2 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $40.03 | 3.8% | 1 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $32.22 | 3.1% | 1 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $28.91 | 2.8% | 2 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $26.79 | 2.5% | 1 | 2025 |
| Kedrion Biopharma, Inc. | Unresolved — no canonical attribution shown | $23.76 | 2.3% | 1 | 2025 |
| MDD US Operations, LLC | Unresolved — no canonical attribution shown | $21.65 | 2.1% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $17.99 | 1.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,048.55 | 44 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $170.45 | 9 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $142.41 | 7 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $93.93 | 3 | 2025 |
Source payment records
|
|||||
| PONVORY Normalized: ponvory |
Drug | Vanda Pharmaceuticals Inc. | $61.21 | 2 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $57.69 | 2 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $55.75 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $43.64 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $43.64 | 2 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $40.03 | 1 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $32.22 | 1 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $28.91 | 2 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $26.79 | 1 | 2025 |
Source payment records
|
|||||
| Albuked Normalized: albuked |
Biological | Kedrion Biopharma, Inc. | $23.76 | 1 | 2025 |
Source payment records
|
|||||
| GAMMAKED Normalized: gammaked |
Biological | Kedrion Biopharma, Inc. | $23.76 | 1 | 2025 |
Source payment records
|
|||||
| KEDRAB Normalized: kedrab |
Biological | Kedrion Biopharma, Inc. | $23.76 | 1 | 2025 |
Source payment records
|
|||||
| KOATE Normalized: koate |
Biological | Kedrion Biopharma, Inc. | $23.76 | 1 | 2025 |
Source payment records
|
|||||
| RhoGAM Ultra-Filtered PLUS Normalized: rhogam ultra filtered plus |
Biological | Kedrion Biopharma, Inc. | $23.76 | 1 | 2025 |
Source payment records
|
|||||
| Gocovri Normalized: gocovri |
Drug | MDD US Operations, LLC | $21.65 | 1 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $17.99 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| SK Life Science, Inc. Exact reporting entity; no affiliate inference |
2025 | XCOPRI open payments reported associated product |
CMS Open Payments — General Payments 1992 supporting records · 782 recipient NPIs · example record 1252276115 |
Xcopri · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Memantine Hcl | Memantine Hcl | 628 | 155 |
| Gabapentin | Gabapentin | 399 | 108 |
| Donepezil Hcl | Donepezil Hcl | 332 | 100 |
| Levetiracetam | Levetiracetam | 316 | 74 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 260 | 49 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 203 | 54 |
| Primidone | Primidone | 194 | 48 |
| Pregabalin | Pregabalin | 186 | 39 |
| Topiramate | Topiramate | 170 | 38 |
| Quetiapine Fumarate | Quetiapine Fumarate | 164 | 43 |
| Clopidogrel | Clopidogrel Bisulfate | 162 | 45 |
| Prednisone | Prednisone | 149 | 99 |
| Tramadol Hcl | Tramadol Hcl | 140 | 57 |
| Tizanidine Hcl | Tizanidine Hcl | 129 | 40 |
| Clonazepam | Clonazepam | 124 | 23 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 122 | 34 |
| Meclizine Hcl | Meclizine Hcl | 100 | 43 |
| Meloxicam | Meloxicam | 92 | 31 |
| Ropinirole Hcl | Ropinirole Hcl | 89 | 21 |
| Amitriptyline Hcl | Amitriptyline Hcl | 86 | 14 |
| Carbamazepine | Carbamazepine | 82 | 18 |
| Divalproex Sodium | Divalproex Sodium | 82 | 19 |
| Oxcarbazepine | Oxcarbazepine | 82 | 22 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 81 | 27 |
| Lamotrigine | Lamotrigine | 72 | 12 |
| Baclofen | Baclofen | 71 | 15 |
| Carisoprodol | Carisoprodol | 71 | 18 |
| Rizatriptan | Rizatriptan Benzoate | 71 | 13 |
| Diazepam | Diazepam | 60 | 20 |
| Sertraline Hcl | Sertraline Hcl | 54 | 15 |
| Lacosamide | Lacosamide | 53 | 13 |
| Methocarbamol | Methocarbamol | 44 | 16 |
| Alprazolam | Alprazolam | 42 | 12 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 39 | suppressed |
| Temazepam | Temazepam | 39 | 13 |
| Aimovig Autoinjector | Erenumab-Aooe | 38 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 36 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 33 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 32 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 30 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 28 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 27 | 13 |
| Dimethyl Fumarate | Dimethyl Fumarate | 26 | suppressed |
| Vumerity | Diroximel Fumarate | 24 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 22 | suppressed |
| Phenobarbital | Phenobarbital | 22 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 20 | suppressed |
| Gamunex-C | Immune Globul G/Gly/Iga Avg 46 | 20 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 20 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 20 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 19 | suppressed |
| Xcopri | Cenobamate | 19 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 17 | suppressed |
| Risperidone | Risperidone | 17 | suppressed |
| Brilinta | Ticagrelor | 16 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 15 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 14 | suppressed |
| Mirtazapine | Mirtazapine | 14 | suppressed |
| Phenytoin | Phenytoin | 14 | suppressed |
| Rivastigmine | Rivastigmine | 14 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Adlarity | Donepezil Hcl | 12 | suppressed |
| Butorphanol Tartrate | Butorphanol Tartrate | 12 | suppressed |
| Carbamazepine Er | Carbamazepine | 12 | suppressed |
| Celecoxib | Celecoxib | 12 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 12 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 12 | suppressed |
| Amantadine | Amantadine Hcl | 11 | suppressed |
| Eliquis | Apixaban | 11 | suppressed |
| Fycompa | Perampanel | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,048.55 · 44 records | SK Life Science, Inc. | ACTHAR, AUSTEDO XR, Albuked, GAMMAKED, Gocovri, INGREZZA, KEDRAB, KESIMPTA, KOATE, Leqembi, NUPLAZID, Ocrevus Zunovo, PONVORY, QULIPTA, RhoGAM Ultra-Filtered PLUS, Rystiggo, UBRELVY, VYEPTI, VYVGART HYTRULO | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with SK Life Science, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error